Unlock instant, AI-driven research and patent intelligence for your innovation.

Acylated long-acting GLP-1 derivative

A technology of GLP-1 and derivatives, which is applied in the field of peptide technology and its derivatives, can solve the problems of limiting action time, etc., and achieve the effects of excellent hypoglycemic ability, significant weight loss ability, and excellent weight loss ability

Active Publication Date: 2022-07-08
BEIJING HUIZHIHENG BIOTECHNOLOGY CO LTD +1
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Since GLP-1 is rapidly degraded by dipeptidyl peptidase 4 (DPP-4) in the body, its action time is greatly limited, making it difficult to be used directly as a drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acylated long-acting GLP-1 derivative
  • Acylated long-acting GLP-1 derivative
  • Acylated long-acting GLP-1 derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1 Preparation of Acylated Long-acting GLP-1 Derivatives

[0071] This example provides a variety of long-acting GLP-1(7-37) derivatives and their preparation methods, especially the construction of a recombinant engineering bacterium that can efficiently express the derivatives of the present invention. The preparation method is as follows (using HS-Y1 as the example):

[0072] (1) Build the code [Tyr 7 Val 8 Glu 22 Arg 26 Lys 30 Arg 34 ]-GLP-1(7-37) expression plasmid

[0073] Through a large amount of research and experiments in the early stage, the present invention selects FKFEFKFE as the inclusion body-promoting sequence and DDDDK as the EK restriction sequence, and fuses the inclusion body-promoting sequence, the EK restriction sequence and the GLP-1 analog coding gene sequence in series in turn to obtain the following sequence: The coding gene fragment shown in SEQ ID NO.3; through the NdeI and XhoI sites, the above-mentioned fragment was inserted ...

Embodiment 2

[0094] Example 2: In vitro cell affinity activity assay

[0095] (1) Preparation of different long-acting GLP-1 derivatives for injection

[0096] The specific formula is: DMEM blank medium, GLP-1 derivatives: 320nM, 64nM, 12.8nM, 2.56nM, 0.512nM, 0.1024nM, 0.02048nM, 0.004096nM. Among them, positive control group (semaglutide), experimental group 1 (HS-Y1), and experimental group 2 (HS-Y2).

[0097] Select HEK293 / Luc / GLP1R cells in good culture condition, discard the culture medium in the bottle, wash once with PBS buffer, add 0.05% Trypsin digestion solution to digest for 3 minutes, then add DMEM basal medium to stop digestion, and collect cells by centrifugation. Adjust the cell density to 8.0 × 10 with DMEM blank medium 5 cells / mL, 50 μL / well were inoculated in 96-well cell culture plates, at 37°C, 5% CO 2 Incubate overnight under conditions.

[0098] Use Fire-Lumi luciferase assay kit to detect the in vitro activity of derivatives of GLP-1 analogs: prepare the assay m...

Embodiment 3

[0104] Example 3: Study of hypoglycemic effect in mice

[0105] (1) Experimental materials:

[0106] a. Experimental drug preparation:

[0107] Prepare injections of different GLP-1 derivatives, the specific formula is 1.133mg / mLNa 2 HPO 4 , 5.5mg / mL phenol, 14.0mg / mL propylene glycol, and GLP-1 derivatives;

[0108] b. Animal experiments:

[0109] Fifty healthy SPF male KM mice aged 6-8 weeks and weighing 18-20g were selected and divided into blank control group, model control group, positive control group (semaglutide group), Example 1 group, Example 1 2 groups of which:

[0110] Blank control group: including 10 mice, gavage with pure water, and subcutaneous injection of blank solvent in the abdomen;

[0111] Model control group: including 10 mice, intragastric administration of glucose (4g / kg), and subcutaneous injection of blank in the abdomen;

[0112] Positive control group: including 10 mice, intragastric administration of glucose (4g / kg), and subcutaneous injec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an acylated long-acting GLP-1 derivative, in particular to a long-acting GLP-1 derivative modified by fatty acid acylation. The long-acting GLP-1 derivative disclosed by the invention has good binding affinity with a GLP-1 receptor and remarkably prolonged action time, and can be used for treating diseases such as diabetes mellitus, impaired glucose tolerance, obesity, hypertension, metabolic syndrome, dyslipidemia and the like.

Description

technical field [0001] The present invention relates to the field of polypeptide technology and derivatives thereof, in particular to an acylated long-acting GLP-1 (7-37) derivative and its preparation method, pharmaceutical composition and medical use. Background technique [0002] Diabetes mellitus is a metabolic disorder of carbohydrates, proteins, fats and other metabolic disorders caused by absolute or relative insufficient insulin secretion and / or insulin utilization disorder. It is mainly marked by hyperglycemia and can be caused by various factors such as heredity and environment. Diabetes is one of the three major fatal diseases in human beings, and its mortality rate is second only to cardiovascular and cerebrovascular diseases and cancer. [0003] Diabetes is mainly divided into type 1 diabetes and type 2 diabetes, most of which are patients with type 2 diabetes (accounting for about 90% according to statistics). Type 2 diabetes (diabetes mellitus type 2, T2DM), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/605C12N15/70C12N1/21A61K38/26A61P3/10A61P3/04C12R1/19
CPCC07K14/605C12N15/70C07K2319/50C07K2319/35Y02A50/30
Inventor 曹海燕林兆生朱志伟王娟王含
Owner BEIJING HUIZHIHENG BIOTECHNOLOGY CO LTD